Correlation Engine 2.0
Clear Search sequence regions

  • 4 and (1)
  • coronavirus (1)
  • cyclic (1)
  • cyclic amp (2)
  • humans (1)
  • IL 1 (1)
  • IL 6 (1)
  • interleukin 17 (2)
  • lung (1)
  • PDE (3)
  • PDE 4 (5)
  • pde4 inhibitors (3)
  • phase (1)
  • pneumonia (1)
  • pneumonia viral (1)
  • risk factors (1)
  • sars cov (1)
  • TNF α (2)
  • Sizes of these terms reflect their relevance to your search.

    The most severe presentation of COVID-19 is characterized by a hyperinflammatory state attributed to the massive pro-inflammatory cytokine release, called "cytokine storm". Several specific anti-inflammatory/immunosuppressive agents are being evaluated by ongoing clinical trials; however, there is currently insufficient evidence for their efficacy and safety in COVID-19 treatment. Given the role of phosphodiesterase 4 (PDE) 4 and cyclic adenosine monophosphate in the inflammatory response, we hypothesize that selective PDE4 inhibition may attenuate the cytokine storm in COVID-19, through the upstream inhibition of pro-inflammatory molecules, particularly TNF-α, and the regulation of the pro-inflammatory/anti-inflammatory balance. Conversely, other anti-cytokine agents lead to the downstream inhibition of specific targets, such as IL-1, IL-6 or TNF-α, and may not be efficient in blocking the cytokine storm, once it has been triggered. Due to their mechanism of action targeting an early stage of the inflammatory response and ameliorating lung inflammation, we believe that selective PDE4 inhibitors may represent a promising treatment option for the early phase of COVID-19 pneumonia before the cytokine storm and severe multiorgan dysfunction take place. Furthermore, PDE4 inhibitors present several advantages including an excellent safety profile; the oral route of administration; the convenient dosing; and beneficial metabolic properties. Interestingly, obesity and diabetes mellitus type 2 have been reported to be risk factors for the severity of COVID-19. Therefore, randomized clinical trials of PDE4 inhibitors are necessary to explore their potential therapeutic effect as an adjunct to supportive measures and other therapeutic regiments. Copyright © 2020 Elsevier Inc. All rights reserved.


    Maria Dalamaga, Irene Karampela, Christos S Mantzoros. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metabolism: clinical and experimental. 2020 Aug;109:154282

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32497535

    View Full Text